You can buy or sell NKTR and other stocks, options, ETFs, and crypto commission-free!
Nektar Therapeutics Common Stock, also called Nektar Therapeutics, is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug candidates. The company focuses on the therapies for cancer, autoimmune disease, and chronic pain. Read More It operates through the United States and Europe geographical segments. The company was founded in 1990 and is headquartered in San Francisco, CA.
San Francisco, California
52 Week High
52 Week Low
Current Fundamentals: Nektar Therapeutics (NASDAQ: NKTR)
Nektar Therapeutics trades as part of the healthcare sector and trades as part of the biotechnology industry. The company CEO is Howard W. Robin. Nektar Therapeutics Inc is a biopharmaceutical company engaged in the development of new molecules to treat diseases with unmet medical needs. The company is researching and developing drugs for treating cancer, auto-immune disease and chronic pain. Previous Intraday Trading Performance: The NKTR stock showed a previous change of 0.62% with an open at 32.10 and ...
Nektar Therapeutics Stock Quote (U.S.: Nasdaq)
All three major indexes climbed around 1%, and the Nasdaq Composite has seen its best start to a year since 2006. The U.S. and China have reportedly made progress on trade negotiations, outweighing negative sentiment from an extended government shutdown.
Yahoo FinanceMar 12
3 Stocks That Could Double Your Money
Nearly every week, a stock soars or sinks because of a Wall Street analyst's opinion. If a key analyst thinks a stock has better prospects than it did the previous week, that view often becomes a self-fulfilling prophecy, with the stock jumping. The opposite scenario frequently happens as well. Since analysts' opinions often carry so much weight, which stocks are they most bullish about? Three stocks that Wall Street especially loves right now are Editas Medicine (NASDAQ: EDIT), Nektar Therapeutics (NASDAQ...
Expected May 9, After Hours